Huang Qi-di, Hu Xiao-qu, Wan Li, Gao Guo-hui, Zheng Shu-rong, You Jie, Guo Gui-long
Department of Surgical Oncology, the First Affiliated Hospital of Wenzhou Medical College, Wenzhou 325000, China.
Zhonghua Wai Ke Za Zhi. 2012 Jan 1;50(1):57-61.
To explore the clinical significance of CC3/TIP30 protein's expression in breast carcinoma and its correlation with HER-2/neu.
The expression of CC3/TIP30 and HER-2/neu protein was detected in 112 breast cancer tissues which was collected from January 2004 to January 2005 by immunohistochemistry and the relationship with clinic pathological parameters and prognosis was analyzed. Small interfering RNA (siRNA) which target to knock out CC3/TIP30 were transfected into SK-BR-3 cells. Real-time PCR were used to detect the level of CC3/TIP30 and HER-2/neu mRNA.
The results of immunohistochemistry showed CC3/TIP30 protein was correlated with TNM stage, lymph node status, HER-2 status and molecule classification (P = 0.048, 0.019, 0.027, 0.011), but there was no association with age, tumor size, estrogen receptor and progesterone receptor. Real-time PCR results revealed that CC3/TIP30 siRNA down-regulation the level of its mRNA, accompanied by a decline in the expression of HER-2/neu gene mRNA, the difference was statistically significant (F = 56.797, P = 0.000; F = 165.101, P = 0.000). In addition, Kaplan-Meier curves of disease-specific survival analysis showed a marked difference in the subtype of HER-2 protein positive between CC3/TIP30 positive group and negative group (χ(2) = 10.732, P = 0.001).
The loss of CC3/TIP30 is related to occurrence and development in breast cancer, suggesting early onset of metastasis and recurrence. Perhaps CC3/TIP30 can be considered as a sub-typing indicator in HER-2 positive breast cancer.
探讨CC3/TIP30蛋白表达在乳腺癌中的临床意义及其与HER-2/neu的相关性。
采用免疫组织化学法检测2004年1月至2005年1月收集的112例乳腺癌组织中CC3/TIP30和HER-2/neu蛋白的表达情况，并分析其与临床病理参数及预后的关系。将靶向敲除CC3/TIP30的小干扰RNA（siRNA）转染至SK-BR-3细胞中。采用实时荧光定量PCR检测CC3/TIP30和HER-2/neu mRNA水平。
免疫组织化学结果显示，CC3/TIP30蛋白与TNM分期、淋巴结状态、HER-2状态及分子分型相关（P = 0.048、0.019、0.027、0.011），但与年龄、肿瘤大小、雌激素受体和孕激素受体无关。实时荧光定量PCR结果显示，CC3/TIP30 siRNA下调其mRNA水平，同时HER-2/neu基因mRNA表达也下降，差异具有统计学意义（F = 56.797，P = 0.000；F = 165.101，P = 0.000）。此外，疾病特异性生存分析的Kaplan-Meier曲线显示，CC3/TIP30阳性组和阴性组HER-2蛋白阳性亚型存在显著差异（χ(2)= 10.732，P = 0.001）。
CC3/TIP30缺失与乳腺癌的发生发展有关，提示早期发生转移和复发。或许CC3/TIP30可被视为HER-2阳性乳腺癌的一种分子分型指标。
